12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The U.K.'s NICE issued final guidance recommending the use of Xarelto rivaroxaban from Bayer to treat pulmonary embolism (PE) and prevent recurrent deep vein thrombosis (DVT) and PE following acute PE...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >